EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Muscle health in the modern era of incretin‐based therapies

Giuseppe De Girolamo iD, Moris Sangineto iD, Giuseppe Di Gioia, Rossella Bianco, Martina Ciarnelli, Gaetano Serviddio

European Journal of Clinical Investigation · 2026-01 · 56 (1)

DOI: 10.1111/eci.70155 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 02.12.2025. Verfasst von Giuseppe De Girolamo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine and Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. Hauptthemen laut MEDLINE: Incretins, Muscle, Skeletal, Obesity, Weight Loss. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intentional weight loss improves obesity‐related outcomes but reduces lean body mass, raising concern about skeletal muscle mass, function and long‐term health. GLP‐1 receptor agonists (GLP‐1RAs) produce clinically meaningful weight loss primarily by lowering energy intake and slowing gastric emptying, with additional benefits on insulin sensitivity and inflammation.

Objective

To clarify GLP‐1RAs' effects on skeletal muscle tissue, body composition and physical function by reviewing preclinical and clinical evidence.

Findings

Across randomized and controlled studies, GLP‐1RAs reduce fat mass more than lean body mass. Functional measures appear preserved. Preclinical and early clinical data suggest improvements in muscle quality (microvascular recruitment, mitochondrial efficiency, reduced intramuscular fat) rather than hypertrophy.

Conclusions

GLP‐1RA‐induced weight loss is largely fat mass with modest absolute lean body mass decline and no consistent deterioration in strength or function. Progressive resistance training, adequate/high‐quality protein and periodic monitoring of body composition and performance should accompany therapy, especially in higher‐risk patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IncretinsMuscle, SkeletalObesityWeight LossGlucagon-Like Peptide-1 Receptor AgonistsHumansBody CompositionMuscle StrengthInsulin Resistance

Stichwörter der Autor:innen

GIPGLP‐1GLP‐1RAmuscle lossweight loss

Substanzen

IncretinsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Internal Medicine and Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
  • Center for Human Nutrition, Washington University School of Medicine, St. Louis, Missouri, USA.

ORCID-Profile: Giuseppe De Girolamo, Moris Sangineto

Zitieren

APA

De Girolamo, G., Sangineto, M., Di Gioia, G., Bianco, R., Ciarnelli, M., & Serviddio, G. (2026). Muscle health in the modern era of incretin‐based therapies. European Journal of Clinical Investigation, 56(1). https://doi.org/10.1111/eci.70155

Vancouver

De Girolamo G, Sangineto M, Di Gioia G, Bianco R, Ciarnelli M, Serviddio G. Muscle health in the modern era of incretin‐based therapies. European Journal of Clinical Investigation. 2026;56(1). doi:10.1111/eci.70155

BibTeX
@article{DeGirolamo2026,
  author = {De Girolamo, Giuseppe and Sangineto, Moris and Di Gioia, Giuseppe and Bianco, Rossella and Ciarnelli, Martina and Serviddio, Gaetano},
  title = {Muscle health in the modern era of incretin‐based therapies},
  journal = {European Journal of Clinical Investigation},
  year = {2026},
  volume = {56},
  number = {1},
  doi = {10.1111/eci.70155}
}
Kostenlos starten →